Therapeutic Effect Of Budesonide Combined With Montelukast On Children With Upper Airway Cough Syndrome

Objective:Comparative observation of clinical efficacy of combined application of budesonide and montelukast in the treatment of upper airway cough syndrome(UACS)in children.Methods:This study selected hospitalized patients from the Department of Respiratory Medicine of Jiangxi Provincial Children's Hospital between January 2016 and September 2017.The clinical data of 90 children with UACS inclusion criteria were analyzed retrospectively.The patients were divided into observation group,control A group and control B group according to the medication situation during the hospitalization period.Each group had 30 patients and the age range was 2 to 12 years old.Among them,the combination of budesonide and montelukast will be used as the observation group,budesonide aerosol inhalation treatment will be the control group A,and montelukast oral treatment will be the control group B,comparing the three groups of UACS children.Situation and etiology,comparison of the time required for cough and nasopharyngeal symptoms after treatment in three groups of children with different modes of treatment,treatment efficacy and incidence of adverse reactions Result:1.Among the 90 children with UACS,48 cases were male and 42 cases were female.The number of males was more than females.Preschool children accounted for 75.6%,which was higher than that of school-age children.2.90 cases of UACS children,all had cough symptoms,66.7% of children with nasal congestion,runny nose,sneezing clinical symptoms;and 53.3% of children with positive physical examination,which the posterior pharyngeal wall The purulent secretion and cobblestone sign were the most common positive signs,accounting for37.8% and 28.9%,respectively.3.After treatment,the symptoms of cough,nose,and pharynx in all three groupswere relieved.The time required to relieve the symptoms in the observation group was significantly shorter than that in the control group A and B(P<0.05).There was no significant difference between the two groups in the control group.(P>0.05).4.After treatment during hospitalization,the total effective rate of budesonide and montelukast observation group was significantly higher than that of the control group(P<0.05),but there was no significant difference between the control group(P>0.05).5.During the hospitalization period,there was no significant difference in the probability of adverse reactions among the three groups of children after their respective treatment programs(P>0.05).Conclusion:1.The cause of more onset of UACS in preschool children lies in the poor resistance of children in this period,easy to be infected by bacteria,virus and so on.The infection can cause the red and swelling of the nasal mucosa and excessive secretion,and the secretions drop down.By stimulating the airway hyperreaction to produce coughing.2.All children with UACS had symptoms of cough,and 2/3 of the children had nasal symptoms(nasal congestion,runny nose,sneezing).Half of the children had positive signs during physical examination.The most common clinical manifestation was pharyngeal pharynx.Sex secretions and cobblestone sign.Tips for children with chronic cough,such as with nasal symptoms,should be alert to the tendency of the upper airway cough syndrome;physical examination if found in the posterior pharynx with purulent secretions or cobblestone sign,we should pay more attention to UACS Diagnosis.3.The combined treatment of budesonide and montelukast significantly improved the clinical symptom improvement time and total treatment efficiency of UACS compared with budesonide or montelukast alone,and did not increase adverse reactions,which may be worthy of clinical promotion.